March 28, 2019 – “The marketing and sale of unapproved opioid addiction treatment products is a potentially significant threat to the public health,” the Food and Drug Administration (FDA) states in a new Warning Letter. “Therefore, FDA is taking measures to protect consumers from products that, without approval by FDA, claim to diagnose, mitigate, prevent, […]
Read more
Oct. 30, 2017 – FDA Commissioner Scott Gottlieb, M.D., is taking a strong leadership position in light of the nation’s opioid crisis, making a statement, in response to President Donald J. Trump’s declaration of the crisis as a public health emergency, that the FDA “has a vital role to play” on this issue, and telling […]
Read more
July 31, 2017 — Guest commentary by Michael Parenti America’s opioid crisis is a major issue and the subject of ongoing debate. But before we can begin to tackle this problem, we need to take a look at the policy decisions that got us here. War has a way of embedding itself within the public consciousness. […]
Read more Last week the FDA made a bold move by requesting that Endo Pharmaceuticals remove its opioid pain medication, reformulated OPANA® ER (oxymorphone hydrochloride), from the market, stating the agency’s concern that “the benefits of the drug may no longer outweigh the risks.” This action – the first time the FDA has taken steps to remove […]
Read moreOct. 17, 2016 – In a recent guest commentary in PM360, Coalition for Healthcare Communication Executive Director John Kamp praised Pfizer for its opioid agreement with the City of Chicago and called on the pharmaceuticals industry to engage now in the fight to help stem the tide of opioid addiction. In the PM360 piece, “In […]
Read moreJuly 8, 2016 – As organized medicine, politicians and the public seek to reverse the scourge of opioid addiction, Pfizer made a move that shows a good-faith effort to become a part of the problem’s solution. The company signed an agreement June 30 with the City of Chicago to follow a written code of conduct […]
Read more